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Overcoming the challenges of membrane protein crystallography
Elisabeth P Carpenter1,2, Konstantinos Beis1,2, Alexander D Cameron1,2
and So Iwata1,2,3Membrane protein structural biology is still a largely
unconquered area, given that approximately 25%of all proteins
are membrane proteins and yet less than 150 unique structures
are available. Membrane proteins have proven to be difficult to
study owing to their partially hydrophobic surfaces, flexibility
and lack of stability. The field is now taking advantage of the
high-throughput revolution in structural biology and methods
are emerging for effective expression, solubilisation,
purification and crystallisation of membrane proteins. These
technical advances will lead to a rapid increase in the rate at
which membrane protein structures are solved in the near
future.
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Introduction
Membrane proteins continue to be among the most
challenging targets in structural biology. All cells and
organelles are contained within a hydrophobic lipid
bilayer. Integral membrane proteins are embedded in
the lipid bilayer, often with additional domains outside
the membrane. These proteins are involved in a wide
variety of biological processes including photosynthesis,
respiration, signal transduction, molecular transport and
catalysis.
Membrane proteins represent between 20 and 30% of the
proteomes of most organisms [1] and more than 40% of
drug targets [2] and yet very few structures of these
molecules have been solved by X-ray crystallography or
Open access under CC BY license.www.sciencedirect.comNMR. The first membrane protein structure was pub-
lished in 1985 [3] and since then the number has
increased slowly but steadily (Figure 1). To date there
are over 50 000 entries in the Protein Data Bank (PDB)
repository of protein structures, but less than 1% of these
entries represent membrane proteins. Of the 368 mem-
brane protein structures in the ‘Membrane proteins of
known 3D structure’ database [4,5] (http://blanco.biomo-
l.uci.edu/Membrane_Proteins_xtal.html), 148 belong to
unique proteins. Eukaryotic membrane proteins are
particularly underrepresented, with only 39 examples
(monotopic and multispanning).
Membrane proteins are difficult to study for a number of
reasons. Their surface is relatively hydrophobic and they
can only be extracted from the cell membrane with
detergents. They are also often flexible and unstable.
This leads to challenges at all levels, including expres-
sion, solubilisation, purification, crystallisation, data col-
lection and structure solution. This review highlights the
issues associated with membrane protein structural
biology and outlines recent approaches that have been
successful in determining new structures.
Expression and purification
Membrane proteins of known structure have been pur-
ified from natural sources, produced recombinantly or, in
the case of short peptides, synthesised chemically. They
have been successfully expressed in the bacteria Escher-
ichia coli and Lactococcus lactis, the yeasts Pichia pastoris
and Saccharomyces cerevisiae, in insect cells and in mam-
malian cell lines (reviewed in Junge et al. [6]). There are
a number of factors that influence the success of an
expression system [7]. Production in E. coli is quick,
relatively inexpensive and easy to use enabling many
constructs to be screened quickly. Eukaryotic proteins
may, however, require the use of eukaryotic systems for
expression. Firstly, membrane proteins have to be tar-
geted to the host cell membrane before they can fold
correctly. Specific systems are required in the host cell
such as the SRP-Sec61 system that inserts membrane
proteins into the endoplasmic reticulum of eukaryotic
cells [8]. Secondly, membrane proteins are embedded in
lipid, and the composition of these lipids varies among the
systems. The nature of the lipids can affect the stability of
the protein and consequently its likelihood of crystal-
lisation. Thirdly eukaryotic proteins may undergo post-
translational modifications, such as glycosylation, and
only higher eukaryotic cell lines provide the necessary
machinery [6]. It is often necessary to experiment with a
variety of expression systems for each protein.Most of theCurrent Opinion in Structural Biology 2008, 18:581–586
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Figure 1
Growth of unique membrane protein structures deposited in the PDB.
Proteins were found by inspection of the ‘Membrane proteins of known
3D structure’ database [4,5] (http://blanco.biomol.uci.edu/
Membrane_Proteins_xtal.html), In blue, the number of structures of
prokaryotic membrane proteins, and in yellow, the total number of
eukaryotic structures. Both monotopic and multispanning proteins are
included. For this study proteins are regarded as unique if they come
from the same family but for different species. Structures are not
counted in these statistics if they represent mutants, alternative
conformations or ligand complexes of a previously counted structure.structures of bacterial membrane proteins that are present
in the PDB were successfully expressed in E. coli. Eukar-
yotic membrane proteins, however, are most commonly
purified from native sources. Of the 39 unique eukaryotic
membrane proteins, only 17 were produced using recom-
binant methods, nine of these in yeast systems (Pichia
pastoris and Saccharomyces cerevisiae) [9–17], four in insect
cells [18,19,20] and four in E. coli [21–24].
Membrane proteins are extracted from the host cell
membrane by the addition of detergents, which cover
the hydrophobic surface of the protein, allowing solubil-
isation. The choice of detergent is a crucial part of the
purification process. Often a series of detergents are
tested and the detergent that extracts the largest quantity
of soluble, active, homogeneous, stable protein is used,
provided that the cost of the detergent is not limiting.
However, it should be noted that some strong detergents
like FOS-Choline are very efficient at extracting proteins
from the membrane, but this does not guarantee stably
solubilised membrane proteins. The detergent dodecyl
maltoside (DDM) is often used to extract membrane
proteins from the lipid bilayer as it is relatively cheap
and can give stably solubilised membrane proteins [25].
Protein can subsequently be exchanged into a variety of
different detergents for crystallisation trials [26].Current Opinion in Structural Biology 2008, 18:581–586Advances are being made in developing methods that can
assess the expression and purification of membrane
proteins in a high-throughput manner [27,28]. The use
of a cleavable green fluorescent protein (GFP) with a his-
tag fused to the C-terminus of the protein has proved to
be very effective as a way of following the protein during
purification, a technique pioneered by Prof. Jan-Willem
De Gier [27] and Eric Gouaux [29]. For this system to be
successful in E. coli expression systems, the target mem-
brane protein must have a cytoplasmic C-terminus, since
the GFP can only be correctly folded and become fluor-
escent in the cytoplasm [30,31]. Prokaryotic and eukar-
yotic GFP fusion proteins expressed in E. coli [32] and
S. cerevisiae [33,34] allow rapid selection of targets with
the highest expression yields for large-scale purification.
In-gel fluorescence analysis and fluorescence size-exclu-
sion chromatography (FSEC) of GFP fusion proteins
clearly showwhether a protein is monodisperse in particu-
lar detergents without the need for prior purification
[29].
An alternative method has been described to rapidly
screen many constructs and conditions for expression
and solubilisation of membrane proteins. The method
was initially described for proteins expressed in 96-well
plates, with small-scale purification in a 96-well format
and detection of proteins blotted onto filters using
antibodies to the purification tag [28]. This method
has since been modified to detect protein expression in
colonies, using the colony filtration blot method [35] in
which colonies are blotted onto membranes, expression
is induced and the cells are lysed with test detergents.
Detergent solubilised proteins are filtered through
membranes and detected with antibodies against the
tag.
Membrane proteins are often unstable in detergent
micelles. Finding constructs or conditions where the
protein is more stable can lead to improved crystallisation
[36]. Sometimes, addition of lipids is essential to obtain
stably solubilised samples [12,37,38,39]. Screening
different buffer and detergent conditions is often necess-
ary and the aggregation state of the material can be
monitored using gel filtration, electron microscopy or
ultracentrifugation [40]. Another way to assess the state
of a protein is to monitor the thermal stability. Stevens
and co-workers have adapted a method for soluble
proteins monitoring the fluorescence of a covalently
bound dye attached to accessible cysteine residues
[41]. In a recent study Tate and co-workers [42]
improved the stability of the b1-adrenergic receptor by
making point mutations and testing the resulting mutants
for activity as a function of temperature. A number of
mutations gave increased thermostability and a combi-
nation of six of these mutations gave a protein with an
increase in Tm of 21 8C. This subsequently enabled the
structure of this protein to be solved [43].www.sciencedirect.com
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Protein crystallisation is a process of testing a large
number of possible crystallisation reagents. Once initial
crystallisation conditions are found, further optimisation
is usually necessary to obtain well-diffracting crystals.
The initial screen is generally completed using 96-well
plates and the vapour diffusion method. In the past 10
years, the volumes required for these crystallisation
experiments have been greatly reduced, so that now
routine screening for crystals is achieved with 100 nl
drops. Although there are more than 30 different 96-well
sparse matrix screening systems available for soluble
proteins, they contain many conditions in which mem-
brane proteins are unlikely to crystallise. The Iwata group
have designed crystallisation screens, which are opti-
mised for membrane protein crystallisation. These in-
clude two sparse matrix screens based on the available
crystallisation conditions at the time of publication
(MemStart [26] and MemGold [44]), and a systematic
screen (MemSys [26]). Screening the detergent used
during crystallisation has proven to be a particularly
important aspect of the process [25]. Often crystal qual-
ity may also be improved with additional detergents
present in the crystallisation drop. Crystallisation ofmem-
brane proteins can also be achieved in the presence of
lipidic cubic or sponge phases or bicelles instead of
detergent micelles [45–47,38]. In the 3D continuous
lipidic phases like the cubic and sponge phases, mem-
brane proteins can freely diffuse in the lipid, instead of
being enclosed in detergent micelle. The proteins mol-
ecules can therefore be concentrated and ordered so that
they can form crystals. These techniques have been
automated so that even viscous lipidic cubic phase
samples can be dispensed in nanodrop quantities [48].
Another technique that is gaining popularity within the
membrane protein community is the use of microfluidics
to combine very small quantities of protein samples, of
the order of 10 nl of protein and crystallisation agent in
50 mm diameter tubes [49,50].
These methods can often lead to crystals that do not
diffract beyond 5 A˚ and are highly anisotropic. Whereas
sometimes optimisation of the conditions with the use of
additives or other detergents can lead to improved resol-
ution, there remain a large number of crystals for which
optimisation is difficult. For these cases it may be necess-
ary to extend the available surface for crystal contacts.
This has been achieved in some cases by forming a stable
complex with the Fab and Fv fragments of an antibody
[51–53,19]. Antibody fragments suitable for co-crystal-
lisation should bind to the protein in its native confor-
mation, have high binding affinity and most importantly
bind to a discontinuous epitope. Fab fragments can be
produced by proteolytic cleavage of monoclonal anti-
bodies though this sometimes generates heterogeneous
products. Since Fabs can also have a high degree of
flexibility at the elbow regions between the variablewww.sciencedirect.comand constant domains [54], Fv fragments may be more
suitable for co-crystallisation since they are globular
25 KDa proteins. Another approach to improving the
likelihood of crystallisation was taken by Mackinnon
and his colleagues in solving the structure of the Kir3.1
K(+) channel. They used chimeras in which part of a
eukaryotic protein was replaced by a prokaryotic counter-
part [22].
Data collection and structure solution
Data collection on soluble protein crystals in a high-
throughput environment is becoming increasingly rou-
tine, with crystals mounted with a sample changer, data
collected automatically and structure solution often semi-
automated (reviewed in [55]). For membrane protein
crystals, the situation is often more challenging. These
crystals usually have a high solvent content owing to the
detergent micelle, which covers the hydrophobic part of
the protein. Consequently, the crystals are often fragile,
difficult to handle, diffract to low resolution and suffer
from radiation damage during the diffraction experiment.
In addition, crystal quality can vary considerably, even
between crystals from the same drop. This means that a
large number of crystals have to be screened at the
synchrotron before data can be collected. The presence
of automatic sample changers at most synchrotron beam-
lines has helped address this issue, enabling many crystals
to be screened quickly and efficiently. The use of modern
microfocus beamlines with low background scatter and
beam sizes of less than 50 mm has also greatly improved
the situation [56]. These beamlines can be used to
collect datasets from very small crystals and from well
diffracting regions in heterogeneous crystals. They can
also be used to collect segments of datasets along the
length of a crystal, when individual regions suffer from
radiation damage [56,43].
The issues mentioned above also affect the process of
structure solution. Owing to the problems of radiation
damage it may be difficult to collect data of sufficient
quality to phase by MAD or SAD. Similarly the problem
of non-isomorphism among the crystals can hinder struc-
ture solution by the isomorphous replacement method.
On the plus side, the high solvent content of membrane
proteins can result in solvent flattening giving large
improvements in the phases.
High-throughput methods for membrane
proteins
One way to overcome the difficulties associated with
membrane protein structural biology is to try a large
number of targets and homologues of each target, in the
hope that a fewwill behave relativelywell through all these
steps. Many soluble protein structural genomics groups
have the necessary technology to clone, express and purify
many protein targets in parallel, with clones being gener-
ated on a 96-well plate scale and crystallisation trials beingCurrent Opinion in Structural Biology 2008, 18:581–586
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[57,58].Many of these techniques are nowbeing applied to
membrane proteins in a number of dedicated membrane
protein initiatives.
We have recently established the Membrane Protein
Laboratory (MPL) at the Diamond Light Source, UK,
which provides a high-throughput environment for
researchers from any laboratory in the world to study
membrane proteins. The MPL has available a fully
automated nanodrop crystallisation system, consisting
of a Hamilton Star liquid handler for plate preparation,
a Cartesian nanodrop robot for preparation of drops as
small as 100 nl, automatic plate sealers and Rhombix
imagers at both 4 and 20 8C, which can record 96 images
from a crystallisation plate in 10 min. These systems are
linked by robotic arms so that up to ten 96-well sitting
drop plates can be prepared in one experiment. We also
use the Fluidigm Topaz system for microfluidic crystal-
lisation [49] where only limited quantities of protein are
available. Potential crystals are screened in crystallisation
plates using the PX scanner system, an in-house X-ray
system. The MPL is located at the new British synchro-
tron, Diamond Light Source, which provides a source of
intense, highly focused X-rays necessary for crystal
screening and data collection on challenging crystals.
The Membrane Protein Laboratory is a user facility
and anyone can apply to use the equipment and have
access the expertise of the membrane protein crystal-
lography (MPC) group at Imperial College London
(http://www.diamond.ac.uk/Science/MPL/default.htm).
Recent advances
One area of membrane protein research in which the
methods described here have had a big impact is in the
structural biology of G-protein-coupled receptors
(GPCRs). GPCRs form the largest family of membrane
proteins in humans and their fundamental role in signal
transduction has made them very attractive drug targets.
They have, however, been notoriously difficult to crystal-
lise, partly owing to their intrinsic flexibility. After many
years of work the first structure of a GPCR that is
regulated by ligand binding, the b2-adrenergic receptor,
was determined past year by two crystallography groups
both collaborating with Brian Kobilka [19,38]. Redu-
cing the flexibility of the protein was instrumental in
solving the structure of this protein. In one of the struc-
tures the third intracellular loop of the protein was stabil-
ized by a Fab fragment [59]. Crystals of the receptor-
Fab complex were obtained from bicelles, a mixture of
detergents and lipids, and data were collected to a resol-
ution of 3.7 A˚ at a microfocus beamline from multiple
regions of one crystal. The other structure was solved as a
fusion protein with T4-lysozyme inserted into the third
intracellular loop, again to stabilize this loop [38,60].
The protein was crystallised in a lipidic cubic phase with
cholesterol used as an additive. Microbeam technologyCurrent Opinion in Structural Biology 2008, 18:581–586was used to collect a single dataset merged from 25
microcrystals to a resolution of 2.4 A˚. This is reviewed
in more detail by Kobilka and Schertler [61].
The structure of the b1-adrenergic receptor has now
also been published. In this case, the protein was
modified by 6-point mutations chosen on the basis of
the increased thermostability of the protein (see above).
The effect of these mutations was firstly to render the
protein more stable in detergents used for crystalliza-
tion and secondly to push the conformational equi-
librium of the protein towards the antagonist bound
state. Data were collected to a resolution of 2.7 A˚ from
crystals of this mutant protein. At the Diamond-MPL,
we are also working on structural studies of GPCRs in
collaboration with the ERATO human crystallography
project (http://cell.mfour.med.kyoto-u.ac.jp/). The
microfocus beamline at Diamond will be a powerful
tool for solving the structures of membrane proteins
including GPCRs.
Conclusion
It is clear that the structure solution of membrane
proteins still holds specific challenges compared with
soluble proteins. The field is now, however, taking
advantage of the high-throughput revolution in structural
biology and is developing a wealth of methods to stabilise
and engineer proteins so that they can be crystallised. We
expect that in the next five years there will be a rapid
growth in the number of solved membrane protein struc-
tures, in particular for eukaryotic membrane proteins.
This will increase our understanding of the folds and
functions in the membrane proteome and provide a
wealth of information for the design of novel drugs.
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